BioSpace News Archive

Acasti Pharma Inc. today announced the successful submission to the FDA of GTX-104’s full protocol of its pivotal Phase 3 Safety Study and implementation of a strategic realignment plan to maximize shareholder value.

Genome Insight announced today the U.S. launch of CancerVision, their innovative whole genome sequencing (WGS) test designed to provide accurate, timely and medically meaningful insights that collectively guide personalized healthcare decisions.

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences.

Deciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 2:30 PM ET in New York, NY.

CareDx, Inc. today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 10, 2023.

Vedanta Biosciences today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (rCDI).

SciSparc Ltd. announced that its joint venture MitoCareX Bio, which focuses on the discovery and development of potential drugs for cancers, rare diseases and other life-threatening conditions, succeeded to develop its core algorithm for allowing the generation of reliable 3D comparative models of human SLC25A mitochondrial carrier proteins - promising transporting targets for innovating therapies.

KalVista Pharmaceuticals, Inc. announced that it made two oral presentations and one poster presentation at the 13th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary.

Zomedica Corp., announced it has exercised its option to move forward with the acquisition of Structured Monitoring Products, Inc., the makers of VetGuardian™ zero-touch vital signs remote monitoring system, at a previously negotiated purchase price.

Pharvaris reported financial results for the first quarter ended March 31, 2023 and provided a business update.